Trial · NCT07912814
Clinical Research on Deep-Plane Rejuran S Injection for Improvement in the Apperance of Periorbital Hollowing Using a Cannula Technique
NCT07912814, Not yet recruiting, PharmaResearch Co.,Ltd
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Clinical Research on Deep-Plane Rejuran S Injection for Improvement in the Apperance of Periorbital Hollowing Using a Cannula Technique. Trials, record NCT07912814. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07912814
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Research on Deep-Plane Rejuran S Injection for Improvement in the Apperance of Periorbital Hollowing Using a Cannula Technique
- NCT number
- NCT07912814
- Status
- Not yet recruiting
- Enrollment
- 30 participants, estimated
- Lead sponsor
- PharmaResearch Co.,Ltd
- Conditions
- Periorbital Hollowing, Skin Aging
- Interventions
- DOT PN (Rejuran S)
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Tear Trough Depth at Week 16 | Baseline (Week 0) and Week 16 | Mean change in tear trough depth (mm) from baseline, measured by QuantifiCare 3D imaging. Week 16 is 4 weeks after the final treatment. |
| Primary | Change From Baseline in Brow Height at Week 16 | Baseline (Week 0) and Week 16 | Mean change in brow height (mm) from baseline, measured by QuantifiCare 3D imaging. Week 16 is 4 weeks after the final treatment. |
| Secondary | Change From Baseline in Tear Trough Depth at Weeks 20 and 24 | Baseline (Week 0), Week 20, and Week 24 | Mean change in tear trough depth (mm) from baseline, measured by QuantifiCare 3D imaging. |
| Secondary | Change From Baseline in Brow Height at Weeks 20 and 24 | Baseline (Week 0), Week 20, and Week 24 | Mean change in brow height (mm) from baseline, measured by QuantifiCare 3D imaging. |
| Secondary | Change From Baseline in Periorbital Wrinkles, Pores, and Brown Spots | Baseline (Week 0), Weeks 16, 20, and 24 | Mean change in periorbital wrinkles, pores, and brown spots from baseline, measured by the QuantifiCare 3D imaging Skincare Module. |
| Secondary | Investigator-Assessed Global Aesthetic Improvement Scale (GAIS) | Weeks 16, 20, and 24 | Aesthetic improvement assessed by the investigator using the 5-point GAIS. |
| Secondary | FACE-Q Eye Module "Satisfaction With Eyes" Score | Weeks 16, 20, and 24 | Subject-reported satisfaction with the appearance of the eyes, measured using the FACE-Q Eye Module "Satisfaction with Eyes" scale. |
| Secondary | Incidence and Severity of Adverse Events (AEs) and Adverse Device Effects (ADEs) | Screening through Week 24 | Number of participants with AEs and ADEs, and their severity, reported throughout the study period. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07912814
GET https://conductscience.org/api/trials/v1/NCT07912814/registered